July 17, ST Huluwa(605199) issued an announcement that it recently received the "Notice of Approval of Drug Supplementary Application" for Ceftriaxone Sodium for Injection approved and issued by the National Drug Administration. The drug has successfully passed the generic drug quality and efficacy consistency evaluation.

The specifications of the drug are 1.0g and 2.0g, the manufacturer is the company, and the original drug approval number is National Medicine Standard H20043257. The approval conclusion of this time confirms that this product meets the consistency evaluation standards according to the provisions of relevant laws and regulations, and agrees to change the drug quality standards and packaging materials that directly contact the drug.and container.

As of the date of disclosure of the announcement, in addition to the company, more than three manufacturers have passed the consistency evaluation of the drug. The company has invested a total of RMB 3.61 million in research and development expenses for the consistency evaluation of the drug (unaudited).

The passing of the consistency evaluation will help improve the market competitiveness of the drug, which is expected to have a positive impact on market sales, and also accumulate experience for the company's subsequent generic drug consistency evaluation work. It should be noted that drug sales are affected by many factors such as industry policies, bidding and procurement, and market environment, and there is great uncertainty.

In the first quarter of 2025, ST Huluwa achieved revenue of 337 million yuan and net profit attributable to shareholders of the parent company of 24.35 million yuan.

https://finance.eastmoney.com/a/202507173459989520.html